Qualification and Implementation of a Robust Multi-Attribute Method Platform Across Multiple Laboratories for High-Resolution Process Characterization of Biopharmaceutical Products
Pharmaceuticals · 2026-07-24 · 19 (8) · 1147
DOI: 10.3390/ph19081147 ↗At a glance
Journal article in Pharmaceuticals, published online on 2026-07-24. Written by François Griaud and 21 co-authors. Institution: Technical Research & Development (TRD) Biologics Analytical Characterization, Novartis Pharma AG, 4002 Basel, Switzerland. Cited 3 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Novartis Pharma AG.
Abstract (original language)
Background/Objectives: Process characterization (PC) of biopharmaceutical products is intended to identify critical process parameters (CPPs) based on their impact on critical quality attributes (CQAs), as well as to define acceptable process parameter ranges to ensure consistent product quality and process performance. However, conventional analytical methods with indirect readouts, e.g., the sum of size/charge variants, often fall short in differentiating CQAs that have safety and efficacy relevance from product quality attributes (PQAs) that do not, thus limiting their utility in establishing a thorough process understanding. The Multi-Attribute Method (MAM) addresses these limitations by monitoring CQAs using the required resolution and specificity.
Methods
A MAM platform was developed, and its robust performance and reproducibility were demonstrated across six laboratories. The MAM platform was applied for the drug substance (DS) PC of two monoclonal antibodies and the analysis of up to a hundred PQAs across 472 and 644 samples, respectively. The MAM results were compared to data obtained with conventional methods like hydrophilic interaction chromatography–fluorescence detection (HILIC-FLD) and cation-exchange chromatography with UV detection (CEX-UV).
Results
The levels of PQAs, including succinimide, deamidation, glycosylation, and oxidation, were reproducible between six laboratories. Artefactual oxidation was limited by controlling the quality of TFA reagent. CPPs impacting the level of, e.g., oxidation, glycation, O-glycosylation, and N-glycan sialylation, were identified, leveraging a simultaneous, consistent, and fast MAM data analysis across all samples.
Conclusions
MAM enables high-resolution PC to identify CPPs and inform control strategies for CQAs that are not resolved by conventional methods.
Subjects
Author keywords
Authors and institutions
- Technical Research & Development (TRD) Biologics Analytical Characterization, Novartis Pharma AG, 4002 Basel, Switzerland.
- TRD Biologics Drug Substance Development, Novartis Pharma AG, 4002 Basel, Switzerland.
- TRD Biologics Process Analytical Sciences, Novartis Pharmaceutical Manufacturing LLC, 1234 Mengeš, Slovenia.
- TRD Biologics Analytical Characterization, Novartis Pharma, 6250 Kundl, Austria.
- Genedata GmbH, 80339 Munich, Germany.
- Genedata AG, 4051 Basel, Switzerland.
ORCID profiles: François Griaud, Stefan Mittermayr, Eva Kranjc, Dariusz Janecki, Thomas Pohl
Funding
- Novartis Pharma AG
Cite
APA
Griaud, F., Merkle, P. S., Ritter, J., Le-Minh, V., Zhang, H., Semanjski Curkovic, M., Mittermayr, S., Kranjc, E., Pirher, N., Pettelkau, J., Nienhaus-Stepath, M., Mertens, D., Rey, G., Dayer, J., Lang, M., Hajduk, J., Jenny, C., Starck, M., Jamnik, T., …, & Pohl, T. (2026). Qualification and Implementation of a Robust Multi-Attribute Method Platform Across Multiple Laboratories for High-Resolution Process Characterization of Biopharmaceutical Products. Pharmaceuticals, 19(8), 1147. https://doi.org/10.3390/ph19081147
Vancouver
Griaud F, Merkle PS, Ritter J, Le-Minh V, Zhang H, Semanjski Curkovic M, et al. Qualification and Implementation of a Robust Multi-Attribute Method Platform Across Multiple Laboratories for High-Resolution Process Characterization of Biopharmaceutical Products. Pharmaceuticals. 2026;19(8):1147. doi:10.3390/ph19081147
BibTeX
@article{Griaud2026,
author = {Griaud, François and Merkle, Patrick Sascha and Ritter, Joachim and Le-Minh, Victor and Zhang, Haiyan and Semanjski Curkovic, Maja and Mittermayr, Stefan and Kranjc, Eva and Pirher, Nina and Pettelkau, Jens and Nienhaus-Stepath, Markus and Mertens, Dominik and Rey, Guillaume and Dayer, Jérôme and Lang, Manuel and Hajduk, Joanna and Jenny, Camille and Starck, Michel and Jamnik, Thomas and Dotzauer, Lukas and Janecki, Dariusz and Pohl, Thomas},
title = {Qualification and Implementation of a Robust Multi-Attribute Method Platform Across Multiple Laboratories for High-Resolution Process Characterization of Biopharmaceutical Products},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1147},
doi = {10.3390/ph19081147}
}
EUVIMED